Split-Dose R-CHOP for Older Patients with Treatment Naive DLBCL

被引：0
|
作者：
Kidwell, Adam [1 ]
Furqan, Fateeha [2 ]
Aschenbrenner, Emilie [3 ]
Longo, Walter [4 ]
Devata, Sumana [3 ]
Hamadani, Mehdi [5 ]
Fenske, Timothy S. [2 ]
Shah, Nirav N. [6 ]
机构：
[1] Froedtert Hosp, Med Coll Wisconsin, Canc Ctr, Milwaukee, WI USA
[2] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA
[3] Med Coll Wisconsin, Milwakee, WI USA
[4] Med Coll Wisconsin, Div Hematol Oncol, Milwaukee, WI USA
[5] Med Coll Wisconsin Inc, Div Hematol & Oncol, Milwaukee, WI USA
[6] Froedtert Hosp, Med Coll Wisconsin, Canc Ctr, Brookfield, WI USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-203974
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2374 / 2375
页数：2
相关论文
共 50 条
  • [31] Correlation of bcl-6 expression with response to R-CHOP in DLBCL
    不详
    CLINICAL LYMPHOMA & MYELOMA, 2006, 7 (02): : 104 - 105
  • [32] Recurrent Patterns of Clonal Evolution in Relapsed-Refractory DLBCL Following Treatment with R-CHOP
    Rushton, Christopher
    Arthur, Sarah E.
    Alcaide, Miguel
    Cheung, Matthew
    Thomas, Nicole
    Hilton, Laura K.
    Michaud, Neil R.
    Daigle, Scott
    Davidson, Jordan
    Bushell, Kevin R.
    Yu, Stephen
    Jain, Michael D.
    Shepherd, Lois E.
    Crump, Michael
    Mann, Koren Kathleen
    Kuruvilla, John
    Assouline, Sarit
    Cleary, Kirstie
    Cragg, Mark S.
    Scott, David W.
    Johnson, Nathalie
    Morin, Ryan D.
    BLOOD, 2019, 134
  • [33] TP53 mutations prognostic for DLBCL treated with R-CHOP
    Nature Reviews Clinical Oncology, 2012, 9 (11) : 611 - 611
  • [34] Response: Outcomes with R-CHOP in DLBCL leave ample room for improvement
    Winter, Jane N.
    Weller, Edie A.
    Horning, Sandre J.
    Gascoyne, Randy D.
    BLOOD, 2007, 109 (02) : 844 - 844
  • [35] Tucidinostat/R-CHOP Combo Appears Effective, Safe in DLBCL Subtype
    不详
    ONCOLOGY-NEW YORK, 2024, 38 (07):
  • [36] OUTCOME OF ELDERLY DLBCL PATIENTS (≥80 YEARS) TREATED WITH ANTHRACYCLINE BASED CHEMOTHERAPY; R-CHOP DOSE REDUCTION IS NOT NECESSARY FOR EVERYBODY
    Trneny, M.
    Janikova, A.
    Sykorova, A.
    Prochazka, V.
    Mocikova, H.
    Klener, P.
    Salek, D.
    Belada, D.
    Benesova, K.
    Pytlik, R.
    Blahovcova, P.
    Boudova, L.
    Campr, V.
    HAEMATOLOGICA, 2017, 102 : 57 - 57
  • [37] Dose attenuation of R-CHOP for the treatment of elderly patients with diffuse large B cell lymphoma
    Choi, Young Jin
    Lee, Kyung Woo
    Shin, Ho-Jin
    Chung, Jooseop
    Cho, Goon-Jae
    BLOOD, 2007, 110 (11) : 184B - 184B
  • [38] DOSE ATTENUATION OF R-CHOP FOR THE TREATMENT OF ELDERLY PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA
    Choi, Y. J.
    Chung, J. S.
    Lee, K. W.
    Shin, H. J.
    Cho, G. J.
    Song, M. K.
    Seol, Y. M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 502 - 502
  • [39] Thrombocytopenia As a Risk Factor for Developing Febrile Neutropenia in Patients with DLBCL Receiving R-CHOP Chemotherapy
    Bailey, Ryan Edward
    Bliven, Sean Patrick
    Narkhede, Mayur
    BLOOD, 2022, 140 : 12122 - 12124
  • [40] CCND2 mRNA Expression Is Correlated With R-CHOP Treatment Efficacy and Prognosis in Patients With ABC-DLBCL
    Wang, Di
    Zhang, Yue
    Che, Yi-Qun
    FRONTIERS IN ONCOLOGY, 2020, 10
12345